Welcome to our dedicated page for VACI news (Ticker: VACI), a resource for investors and traders seeking the latest updates and insights on VACI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VACI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VACI's position in the market.
Viking Acquisition Corp. I (NYSE: VACI.U) priced an initial public offering of 20,000,000 units at $10.00 per unit, representing aggregate gross proceeds of $200,000,000. Each unit contains one Class A ordinary share and one‑third of one redeemable warrant; whole warrants exercisable to buy one Class A share at $11.50 per share, subject to adjustment.
The units are expected to begin trading on the New York Stock Exchange under the ticker VACI.U on October 31, 2025; when separated, shares and warrants are expected to trade as VACI and VACI WS. Cohen & Company Capital Markets is sole book‑running manager. The underwriters have a 45‑day option to purchase up to 3,000,000 additional units. The offering is expected to close on November 3, 2025, subject to customary conditions and S‑1 effectiveness.
